secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2022-01-11T23:59:59+00:00
Accession:  0001384101-22-000004
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte appoints Tina Nova as President of CLIA U.S. business
--------------------------------------------------------------

- Tina S. Nova, Ph.D., appointed President of Veracyte's CLIA U.S. business effective January 6, 2022.
- Dr. Nova previously served as General Manager, Thyroid and Urologic Cancers since March 2021.
- She was on Veracyte's board from Nov 2015 to Feb 2021 and was CEO of Decipher before its acquisition.
- Dr. Nova will enter into standard indemnification agreement; no family relationships or material transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410122000004/0001384101-22-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410122000004/vcyt-20220106.htm
  HTML page:      https://secwatch.observer/filing/0001384101-22-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer